Avantor Valuation

Q: What is the Fair Price of AVG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

AVG (€22.6) is trading below our estimate of [[fair value]] (€45.26)

Is AVG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AVG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AVG (€22.6) is trading below our estimate of fair value (€45.26)

Significantly Below Fair Value: AVG is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AVG?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for AVG. This is calculated by dividing AVG's market cap by their current preferred multiple.
What is AVG's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$14.14b

AVG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.8x
Enterprise Value/EBITDA	15.8x
PEG Ratio	1.6x

Price to Earnings Ratio vs Peers

How does AVG's PE Ratio compare to its peers?

The above table shows the PE ratio for AVG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	44x
1SXP SCHOTT Pharma KGaA	31.5x	15.9%	€4.7b
GXI Gerresheimer	30.5x	22.2%	€3.5b
DIVISLAB Divi's Laboratories	86.4x	21.7%	₹1.4t
MRK Merck KGaA	27.6x	11.8%	€72.5b
AVG Avantor	54.4x	34.8%	€14.1b

Price-To-Earnings vs Peers: AVG is good value based on its Price-To-Earnings Ratio (54.4x) compared to the peer average (62.9x).

Price to Earnings Ratio vs Industry

How does AVG's PE Ratio compare vs other companies in the European Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.9%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: AVG is expensive based on its Price-To-Earnings Ratio (54.4x) compared to the European Life Sciences industry average (40x).

Price to Earnings Ratio vs Fair Ratio

What is AVG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVG PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	54.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AVG's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.